

Pharmaceutical Management Agency  
New Zealand  
Pharmaceutical Schedule

# Section H Update

for Hospital Pharmaceuticals

December 2021

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a background of stylized, wavy, concentric lines in shades of gray and white.

PHARMAC  
TE PĀTAKA WHAIORANGA

# Contents

Summary of decisions effective 1 December 2021 .....	3
Section H changes to Part II .....	5
Index .....	10

## Summary of decisions

### EFFECTIVE 1 DECEMBER 2021

- Amikacin (Biomed) inj 5 mg per ml, 5 ml syringe – price increase
  - Amiloride hydrochloride (Biomed) oral liq 1 mg per ml, 25 ml – price increase
  - Amnio acid formula powder (Alfamino, Neocate Gold (Unflavoured), Neocate Junior Vanilla, Alfamino Junior, Elecare LCP (Unflavoured), Elecare (Unflavoured) and Elecare (Vanilla)) – amended restriction criteria
  - Amisulpride (Sulprix) tab 200 mg (Pharmacode 2609398) – new Pharmacode listing
  - Amisulpride (Sulprix) tab 200 mg (Pharmacode 2500140) – Pharmacode to be delisted 1 August 2022.
  - Buspirone hydrochloride (Buspirone Viatris) tab 5 mg and 10 mg – new listing and addition of PSS
  - Buspirone hydrochloride (Orion) tab 5 mg and 10 mg – to be delisted 1 May 2022
  - Calamine (Calamine-AFT) crm, aqueous, BP, 100 g – new listing and addition of PSS
  - Calamine (healthE) crm, aqueous, BP, 100 g – to delisted 1 May 2022
  - Cetomacrogol (Cetomacrogol-AFT) crm BP, 500 g – new listing and addition of PSS
  - Cetomacrogol (healthE) crm BP, 500 g – to be delisted 1 May 2022
  - Clozapine (Clopine) oral liq 50 mg per ml, 100 ml – to be delisted 1 April 2022
  - Chlorothiazide (Biomed) oral liq 50 mg per ml, 25 ml – price increase
  - Darunavir (Darunavir Mylan) tab 400 mg (Pharmacode 2595486) – Pharmacode to be delisted 1 June 2022
  - Dexamethasone (Biomed) oral liq 1 mg per ml, 25 ml – price increase
  - Diltiazem hydrochloride (Accord) cap extended-release 120 mg, 100 cap pack – new listing
  - Ethinyloestradiol with levonorgestrel (Microgynon 50 ED) tab 50 mcg with levonorgestrel 125 mcg, 84 tab pack – to be delisted 1 March 2022
  - Ferrous fumarate (Ferro-tab) tab 200 mg (65 mg elemental) – price decrease and addition of PSS
  - Flucloxacillin (Flucloxacillin-AFT) cap 250 mg and 500 mg – new listing and addition of PSS
  - Flucloxacillin (Staphlex) cap 250 mg and 500 mg – price decrease and to be delisted 1 May 2022
  - Folic acid (Biomed) oral liq 50 mcg per ml, 25 ml – price increase
-

## Summary of decisions – effective 1 December 2021 (continued)

- Ketamine (Ketamine-Baxter) inj 100 mg per ml, 2 ml ampoule – delist delayed from 1 January 2022 to 1 July 2022
- Lidocaine [lignocaine] hydrochloride (Lidocaine-Clarix) inj 2%, 20 ml vial, 5 pack – to be delisted 1 June 2022
- Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride (Topicaine) soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – price increase
- Moclobemide (Aurorix) tab 300 mg, 60 pack (Pharmacode 2602393) – new Pharmacode listing
- Moclobemide (Aurorix) tab 300 mg, 60 pack (Pharmacode 2560437) – Pharmacode to be delisted 1 June 2022
- Prazosin (Arrotex-Prazosin S29) tab 1 mg, 2 mg and 5 mg – brand name change
- Prednisone (Prednisone Clinect) tab 1 mg, 2.5 mg, 5 mg and 20 mg – new listing
- Prednisone (Apo-Prednisone) tab 1 mg, 2.5 mg, 5 mg and 20 mg – to be delisted 1 November 2022
- Rosuvastatin (Rosuvastatin Viatrix) tab 5 mg, 10 mg, 20 mg and 40 mg – new listing
- Ruxolitinib (Jakavi) tab 10 mg, 56 pack – new listing
- Sodium bicarbonate (Biomed) inj 8.4%, 50 ml vial and 100 ml vial – price increase
- Sodium chloride (Biomed) inj 23.4% (4 mmol/ml), 20 ml ampoule – price increase
- Tropicsetron (Tropicsetron-AFT) inj 1 mg per ml, 2 ml ampoule and 5 ml ampoule – brand to be delisted 1 December 2021
- Vigabatrin tab 500 mg – amended restriction criteria

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Section H changes to Part II

Effective 1 December 2021

### ALIMENTARY TRACT AND METABOLISM

21	FERROUS FUMARATE (↓ price and addition of PSS) Tab 200 mg (65 mg elemental) – <b>5% DV May-22 to 2024</b> .....	3.04	100	<b>Ferro-tab</b>
----	--	------	-----	------------------

### BLOOD AND BLOOD FORMING ORGANS

28	FOLIC ACID (↑ price) Oral liq 50 mcg per ml .....	27.82	25 ml	Biomed
39	SODIUM BICARBONATE (↑ price) Inj 8.4%, 50 ml vial .....	21.40	1	Biomed
	Inj 8.4%, 100 ml vial .....	21.95	1	Biomed
39	SODIUM CHLORIDE (↑ price) Inj 23.4% (4 mmol/ml), 20 ml ampoule .....	35.50	5	Biomed

### CARDIOVASCULAR SYSTEM

44	PRAZOSIN (brand name change) Tab 1 mg .....	5.53	100	Apo-Prazosin-S29 <b>Arrotex-Prazosin S29</b>
	Tab 2 mg .....	7.00	100	Apo-Prazosin-S29- <b>Arrotex-Prazosin S29</b>
	Tab 5 mg .....	11.70	100	Apo-Prazosin-S29 <b>Arrotex-Prazosin S29</b>
47	DILTIAZEM HYDROCHLORIDE (new listing) Cap extended-release 120 mg .....	44.40	100	Accord
48	AMILORIDE HYDROCHLORIDE (↑ price) Oral liq 1 mg per ml .....	32.10	25 ml	Biomed
48	CHLOROTHIAZIDE (↑ price) Oral liq 50 mg per ml .....	27.82	25 ml	Biomed

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 December 2021 (continued)

48	ROSUVASTATIN (new listing)			
	→ Tab 5 mg – 1% DV May-22 to 2023	1.70	30	Rosuvastatin Viatris
	→ Tab 10 mg – 1% DV May-22 to 2023	2.42	30	Rosuvastatin Viatris
	→ Tab 20 mg – 1% DV May-22 to 2023	3.92	30	Rosuvastatin Viatris
	→ Tab 40 mg – 1% DV May-22 to 2023	5.28	30	Rosuvastatin Viatris

### Restricted

Initiation - cardiovascular disease risk

Either:

1. Both:

- 1.1. Patient is considered to be at risk of cardiovascular disease; and
- 1.2. Patient is Māori or any Pacific ethnicity; or

2. Both:

- 2.1. Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years; and
- 2.2. LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initiation - familial hypercholesterolemia

Both:

1. Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6); and
2. LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initiation - established cardiovascular disease

Both:

1. Any of the following:

- 1.1. Patient has proven coronary artery disease (CAD); or
- 1.2. Patient has proven peripheral artery disease (PAD); or
- 1.3. Patient has experienced an ischaemic stroke; and

2. LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initiation - recurrent major cardiovascular events

Both:

1. Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary revascularisation, hospitalisation for unstable angina) in the last 2 years; and
2. LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

## DERMATOLOGICALS

56	CALAMINE (brand change and addition of PSS) Crm, aqueous, BP – 5% May-22 to 2024	1.08	100 g	Calamine-AFT
	Note – healthE Calamine Aqueous Cream BP, 100 g to be delisted 1 May 2022.			
57	CETOMACROGOL (brand change and addition of PSS) Crm BP, 500 g – 5% DV May-22 to 2024	1.99	500 g	Cetomacrogol-AFT
	Note – healthE crm BP, 500 g to be delisted 1 May 2022.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

## Changes to Section H Part II – effective 1 December 2021 (continued)

### GENITO-URINARY SYSTEM

64	ETHINYLOESTRADIOL WITH LEVONORGESTREL (delisting) Tab 50 mcg with levonorgestrel 125 mcg.....	9.45	84	Microgynon 50 ED
	Note – Microgynon 50 ED tab 50 mcg with levonorgestrel 125 mcg to be delisted 1 March 2022.			

### HORMONE PREPARATIONS

67	DEXAMETHASONE († price) Oral liq 1 mg per ml .....	48.15	25 ml	Biomed
70	PREDNISONE (brand change) Tab 1 mg..... Tab 2.5 mg..... Tab 5 mg..... Tab 20 mg.....	18.58 21.04 19.30 50.51	500 500 500 500	Prednisone Clinect Prednisone Clinect Prednisone Clinect Prednisone Clinect
	Note – Apo-Prednisone tab 1 mg, 2.5 mg, 5 mg and 20 mg to be delisted 1 November 2022.			

### INFECTIONS

76	AMIKACIN († price) → Inj 5 mg per ml, 5 ml syringe .....	19.43	1	Biomed
80	FLUCLOXACILLIN Cap 250 mg – <b>5% May-22 to 2024</b> (new listing and addition of PSS)..... (↓ price and delisting) Cap 500 mg – <b>5% May-22 to 2024</b> (new listing and addition of PSS)..... (↓ price and delisting)	15.79 52.99	250 500	<b>Flucloxacillin-AFT</b> Staphlex <b>Flucloxacillin-AFT</b> Staphlex
	Note – Staphlex cap 250 mg and 500 mg to be delisted 1 May 2022.			
93	DARUNAVIR (Pharmacode delisting) → Tab 400 mg – <b>1% DV Apr-21 to 2023</b> .....	132.00	60	<b>Darunavir Mylan</b>
	Note – Pharmacode 2595486 to be delisted 1 June 2022.			

### NERVOUS SYSTEM

111	KETAMINE (delist delayed) Inj 100 mg per ml, 2 ml ampoule .....	28.50	5	Ketamine-Baxter
	Note – this delisting is delayed from 1 January 2022 to 1 July 2022.			
112	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE († price) Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe .....	18.75	1	Topicaine

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 December 2021 (continued)

113	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (delisting) Inj 2%, 20 ml vial .....	6.45	5	Lidocaine-Claris
	Note – Lidocaine-Claris inj 2%, 20 ml vial to be delisted 1 June 2022.			
118	MOCLOBEMIDE (Pharmacode change) Tab 300 mg – <b>5% DV Jan-22 to 2024</b> .....	19.25	60	<b>Aurorix</b>
	Note – this is a new listing for Pharmacode 2602393. Pharmacode 2560437 to be delisted 1 June 2022.			
122	VIGABATRIN (amended restriction criteria – affected criteria shown only) → Tab 500 mg Restricted Initiation <i>Re-assessment required after 15 months</i> Both: 1 <b>Either: Any of the following:</b> 1.1 Patient has infantile spasms; or 1.2 Both: 1.2.1 Patient has epilepsy; and 1.2.2 Either: 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; <b>and or</b> <b>1.3 Patient has tuberous sclerosis complex; and</b> 2 <b>Either:</b> 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.			
124	TROPISETRON (brand delisting) Inj 1 mg per ml, 2 ml ampoule .....	8.95	1	Tropisetron-AFT
	Inj 1 mg per ml, 5 ml ampoule .....	13.95	1	Tropisetron-AFT
	Note – Tropisetron-AFT inj 1 mg per ml, 2 ml ampoule and 5 ml ampoule to be delisted 1 December 2021 (brand only).			
124	AMISULPRIDE (Pharmacode change) Tab 200 mg – <b>1% DV Nov-19 to 2022</b> .....	14.96	60	<b>Sulprix</b>
	Note – this listing is for Pharmacode 2609398. Pharmacode 2500140 to be delisted 1 August 2022.			
125	CLOZAPINE (delisting) Oral liq 50 mg per ml .....	17.33	100 ml	Clopine
	Note – Clopine oral liq 50 mg per ml, 100 ml is to be delisted 1 April 2022.			



	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

## Changes to Section H Part II – effective 1 December 2021 (continued)

127	BUSPIRONE HYDROCHLORIDE (brand change and addition of PSS)			
	Tab 5 mg – 5% <b>May-22 to 2024</b> .....	18.50	100	<b>Buspirone Viatris</b>
	Tab 10 mg – 5% <b>May-22 to 2024</b> .....	12.50	100	<b>Buspirone Viatris</b>
	Note – Orion tab 5 mg and 10 mg to be delisted 1 May 2022.			

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

147	RUXOLITINIB (new listing)			
	→ Tab 10 mg.....	5,000.00	56	Jakavi

## SPECIAL FOODS

248	AMINO ACID FORMULA (amended restriction criteria – new criteria shown only)			
	→ Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can			<i>e.g. Neocate</i>
	→ Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g can			<i>e.g. Neocate SYNEO unflavoured</i>
	→ Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can			<i>e.g. Neocate Junior Unflavoured</i>
	→ Powder 13.3 g protein, 57 g carbohydrate and 24.6 g fat per 100 g, can.....	43.60	400 g	Alfamino
	→ Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can.....	53.00	400 g	Neocate Gold (Unflavoured)
	→ Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per 100 g, can.....	53.00	400 g	Neocate Junior Vanilla
	→ Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can.....	43.60	400 g	Alfamino Junior
	→ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can.....	53.00	400 g	Elecare LCP (Unflavoured)
	→ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can.....	53.00	400 g	Elecare (Unflavoured) Elecare (Vanilla)

### Restricted

Initiation – patients who are currently funded under RS1502 or SA1557

Limited to 3 months treatment

All of the following:

1. Patient has a valid initiation or renewal approval for extensively hydrolysed formula (RS1502); and
2. Patient is unable to source funded Aptamil powder at this time; and
3. The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo.

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Hospital Restriction RS1502. There is no continuation criteria under this criterion.

# Index

## Pharmaceuticals and brands

<b>A</b>	
Alfamino .....	9
Alfamino Junior.....	9
Amikacin.....	7
Amiloride hydrochloride.....	5
Amino acid formula.....	9
Amisulpride.....	8
Apo-Prazosin S29.....	5
Arrotex-Prazosin S29.....	5
Aurorix.....	8
<b>B</b>	
Buspirone hydrochloride.....	9
Buspirone Viatrix.....	9
<b>C</b>	
Calamine.....	6
Calamine-AFT.....	6
Cetomacrogol.....	6
Cetomacrogol-AFT.....	6
Chlorothiazide.....	5
Clopine.....	8
Clozapine.....	8
<b>D</b>	
Darunavir.....	7
Darunavir Mylan.....	7
Dexamethasone.....	7
Diltiazem hydrochloride.....	5
<b>E</b>	
Elecare LCP (Unflavoured).....	9
Elecare (Unflavoured).....	9
Elecare (Vanilla).....	9
Ethinylloestradiol with levonorgestrel.....	7
<b>F</b>	
Ferro-tab.....	5
Ferrous fumarate.....	5
Flucloxacillin.....	7
Flucloxacillin-AFT.....	7
Folic acid.....	5
<b>J</b>	
Jakavi.....	9
<b>K</b>	
Ketamine.....	7
Ketamine-Baxter.....	7
<b>L</b>	
Lidocaine-Claris.....	8
Lidocaine [Lignocaine] hydrochloride.....	8
Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride.....	7
Lignocaine.....	7, 8
<b>M</b>	
Microgynon 50 ED.....	7
Moclobemide.....	8
<b>N</b>	
Neocate.....	9
Neocate Gold (Unflavoured).....	9
Neocate Junior Unflavoured.....	9
Neocate Junior Vanilla.....	9
Neocate SYNEO unflavoured.....	9
<b>P</b>	
Prazosin.....	5
Prednisone.....	7
Prednisone Clinect.....	7
<b>R</b>	
Rosuvastatin.....	6
Rosuvastatin Viatrix.....	6
Ruxolitinib.....	9
<b>S</b>	
Sodium bicarbonate.....	5
Sodium chloride.....	5
Staphlex.....	7
Sulprix.....	8
<b>T</b>	
Topicaine.....	7
Tropisetron.....	8
Tropisetron-AFT.....	8
<b>V</b>	
Vigabatrin.....	8

New Zealand  
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

Email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

ISSN 1172-3694 (Print)

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand